A Novel Mechanism of G Protein-coupled Receptor Functional Selectivity

Many G protein-coupled receptors (GPCRs) possess allosteric binding sites distinct from the orthosteric site utilized by their cognate ligands, but most GPCR allosteric modulators reported to date lack signaling efficacy in their own right. McN-A-343 (4-(N-(3-chlorophenyl)carbamoyloxy)-2-butynyltrimethylammonium chloride) is a functionally selective muscarinic acetylcholine receptor (mAChR) partial agonist that can also interact allosterically at the M2 mAChR. We hypothesized that this molecule simultaneously utilizes both an allosteric and the orthosteric site on the M2 mAChR to mediate these effects. By synthesizing progressively truncated McN-A-343 derivatives, we identified two, which minimally contain 3-chlorophenylcarbamate, as pure allosteric modulators. These compounds were positive modulators of the orthosteric antagonist N-[3H]methylscopolamine, but in functional assays of M2 mAChR-mediated ERK1/2 phosphorylation and guanosine 5′-3-O-([35S]thio)triphosphate binding, they were negative modulators of agonist efficacy. This negative allosteric effect was diminished upon mutation of Y177A in the second extracellular (E2) loop of the M2 mAChR that is known to reduce prototypical allosteric modulator potency. Our results are consistent with McN-A-343 being a bitopic orthosteric/allosteric ligand with the allosteric moiety engendering partial agonism and functional selectivity. This finding suggests a novel and largely unappreciated mechanism of “directed efficacy” whereby functional selectivity may be engendered in a GPCR by utilizing an allosteric ligand to direct the signaling of an orthosteric ligand encoded within the same molecule.

[1]  Kurt Kristiansen,et al.  Molecular mechanisms of ligand binding, signaling, and regulation within the superfamily of G-protein-coupled receptors: molecular modeling and mutagenesis approaches to receptor structure and function. , 2004, Pharmacology & therapeutics.

[2]  N. Birdsall,et al.  International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. , 1998, Pharmacological reviews.

[3]  R. Stevens,et al.  High-Resolution Crystal Structure of an Engineered Human β2-Adrenergic G Protein–Coupled Receptor , 2007, Science.

[4]  Xavier Deupi,et al.  Probing the β2 Adrenoceptor Binding Site with Catechol Reveals Differences in Binding and Activation by Agonists and Partial Agonists* , 2005, Journal of Biological Chemistry.

[5]  A. Christopoulos,et al.  Transducer abstraction: a novel approach to the detection of partial agonist efficacy in radioligand binding studies. , 2000, Journal of pharmacological and toxicological methods.

[6]  A. Christopoulos,et al.  Pharmacological analysis of the mode of interaction of McN-A-343 at atrial muscarinic M2 receptors. , 1997, European journal of pharmacology.

[7]  F. Ehlert,et al.  Estimation of Agonist Activity at G Protein-Coupled Receptors: Analysis of M2 Muscarinic Receptor Signaling through Gi/o,Gs, and G15 , 2007, Journal of Pharmacology and Experimental Therapeutics.

[8]  L. Bačáková,et al.  Subtype selectivity of the positive allosteric action of alcuronium at cloned M1-M5 muscarinic acetylcholine receptors. , 1995, The Journal of pharmacology and experimental therapeutics.

[9]  P. Jeffrey Conn,et al.  N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-d-aspartate receptor activity , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[10]  Arthur Christopoulos,et al.  Critical Role for the Second Extracellular Loop in the Binding of Both Orthosteric and Allosteric G Protein-coupled Receptor Ligands* , 2007, Journal of Biological Chemistry.

[11]  A. Roszkowski,et al.  STRUCTURE-ACTIVITY RELATIONSHIPS AMONG A SERIES OF ACETYLENIC CARBAMATES RELATED TO McN-A-343 , 1967 .

[12]  P. Sexton,et al.  Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology. , 2007, Trends in pharmacological sciences.

[13]  A. Christopoulos,et al.  Qualitative and quantitative assessment of relative agonist efficacy. , 1999, Biochemical pharmacology.

[14]  Arthur Christopoulos,et al.  Functional Selectivity and Classical Concepts of Quantitative Pharmacology , 2007, Journal of Pharmacology and Experimental Therapeutics.

[15]  S. Lazareno,et al.  Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligands at G protein-coupled receptors: interactions of strychnine and acetylcholine at muscarinic receptors. , 1995, Molecular pharmacology.

[16]  K. Palczewski,et al.  Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2002, Chembiochem : a European journal of chemical biology.

[17]  H. Tecle,et al.  Mutations of aspartate 103 in the Hm2 receptor and alterations in receptor binding properties of muscarinic agonists. , 1995, Life sciences.

[18]  R. Abagyan,et al.  Biased probability Monte Carlo conformational searches and electrostatic calculations for peptides and proteins. , 1994, Journal of molecular biology.

[19]  M. M. Bradford A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[20]  C. Langmead,et al.  Structure-Function Studies of Allosteric Agonism at M2 Muscarinic Acetylcholine Receptors , 2007, Molecular Pharmacology.

[21]  C. Langmead,et al.  Allosteric agonists of 7TM receptors: expanding the pharmacological toolbox. , 2006, Trends in pharmacological sciences.

[22]  J. Wess Allosteric Binding Sites on Muscarinic Acetylcholine Receptors , 2005, Molecular Pharmacology.

[23]  A. Christopoulos Assessing the distribution of parameters in models of ligand-receptor interaction: to log or not to log. , 1998, Trends in pharmacological sciences.

[24]  C. Guenet,et al.  Site-directed mutagenesis of the putative human muscarinic M2 receptor binding site. , 1999, European journal of pharmacology.

[25]  P. Leff,et al.  Estimation of partial agonist affinity by interaction with a full agonist: a direct operational model‐fitting approach , 1993, British journal of pharmacology.

[26]  Arthur Christopoulos,et al.  Allosteric modulation of G protein-coupled receptors. , 2007, Annual review of pharmacology and toxicology.

[27]  A. Roszkowski An unusual type of sympathetic ganglionic stimulant. , 1961, The Journal of pharmacology and experimental therapeutics.

[28]  M. Waelbroeck Identification of drugs competing with d-tubocurarine for an allosteric site on cardiac muscarinic receptors. , 1994, Molecular pharmacology.

[29]  T. Kenakin,et al.  G Protein-Coupled Receptor Allosterism and Complexing , 2002, Pharmacological Reviews.

[30]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[31]  E. Hulme,et al.  The effect of McN‐A‐343 on muscarinic receptors in the cerebral cortex and heart , 1983, British journal of pharmacology.

[32]  J. Saldanha,et al.  Seven-transmembrane receptors: crystals clarify. , 2002, Trends in pharmacological sciences.

[33]  E. Kostenis,et al.  Evidence for a multiple binding mode of bispyridinium-type allosteric modulators of muscarinic receptors. , 1996, European journal of pharmacology.

[34]  J. Black Drugs from emasculated hormones: the principle of syntopic antagonism. , 1989, Bioscience reports.